Literature DB >> 7448802

Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice.

C K Leung, R P Shiu.   

Abstract

Estrogen, prolactin, and other pituitary factors are implicated in the etiology of human breast cancer. In the present study, the effects of estrogen and factors from GH3 rat pituitary tumor cells on the growth of T-47D human breast cancer cells were tested in athymic nude mice. Four groups of nude mice were used: Group 1 (T) received s.c. injection of T-47D cells only; Group 2 (TE) mice were given injections of estradiol valerate and T-47D cells; Group 3 mice were given injections of T-47D and GH3 cells (TG), one cell type on each flank; and Group 4 received estradiol valerate and T-47D and GH3 cells (TEG). We found that the human breast cancer cells, T-47D, did not proliferate in Groups 1 and 3 despite the presence of high circulating levels of prolactin and growth hormone produced by the growing GH3 pituitary tumors in Group 3. This suggested that prolactin and growth hormone were not sufficient to stimulate the growth of human breast cancer cells. T-47D cells exhibited only moderate growth in Group 2 but proliferated rapidly in Group 4. The T-47D tumors of Group 4 were 8 times larger than those in Group 2 after 42 days of growth. These results demonstrate that the simultaneous presence of estrogen and pituitary growth factors are required for maximal growth of T-47D human breast cancer cells in nude mice. The identity of the pituitary-dependent growth factor(S) that stimulates the growth in vivo of human breast cancer cells remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7448802

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

2.  Identification of estrogen-inducible growth factors (estromedins) for rat and human mammary tumor cells in culture.

Authors:  T Ikeda; Q F Liu; D Danielpour; J B Officer; M Iio; F E Leland; D A Sirbasku
Journal:  In Vitro       Date:  1982-12

Review 3.  Endocrine therapy of human breast cancer grown in nude mice.

Authors:  N Brünner; C K Osborne; M Spang-Thomsen
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

Review 4.  Studies of human breast cancer metastasis using nude mice.

Authors:  J E Price; R D Zhang
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

5.  Transplantation of ACTH-secreting pituitary tumor cells in athymic nude mice.

Authors:  C K Leung; J A Paterson; Y Imai; R P Shiu
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982-08

6.  Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age.

Authors:  B Rae-Venter; T Nemoto; S L Schneider; T L Dao
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

7.  Primate mammary development. Effects of hypophysectomy, prolactin inhibition, and growth hormone administration.

Authors:  D L Kleinberg; W Niemann; E Flamm; P Cooper; G Babitsky; Q Valensi
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells.

Authors:  R Mira-y-Lopez; J Joseph-Silverstein; D B Rifkin; L Ossowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 9.  Considerations in the use of nude mice for cancer research.

Authors:  F E Sharkey; J Fogh
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

10.  Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer.

Authors:  H J van Slooten; B A Bonsing; A J Hiller; G T Colbern; J H van Dierendonck; C J Cornelisse; H S Smith
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.